European Archives - Page 91 of 1447 - European Medical Journal

deep brain stimulation

What Are the Risks of Deep Brain Stimulation?

Discover why deep brain stimulation may be safer than expected and how large scale data could change surgical decision making.

Machine Learning Aids Prognosis in Upper Tract Urothelial Cancer

Machine learning models accurately predict survival after surgery for upper tract urothelial cancer, supporting personalised follow up and adjuvant treatment decisions.

Hidden Mpox Exposure Found Among Healthy Adults

New sero-genomic research suggests hidden mpox exposure in healthy Nigerian adults, highlighting residual smallpox immunity and surveillance gaps.

CAR-T Cell Therapy Induces Durable Remission in SLE

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.

Optimising Continuous Infusion Therapy in Advanced Parkinson’s Disease

This infographic offers consensus-based guidance on the real-world use of LDp/CDp for patients with advanced…

Hetrombopag Effective in Paediatric Immune Thrombocytopenia

Hetrombopag achieved an overall response in over three quarters of paediatric patients with immune thrombocytopenia, with durable responses and no serious adverse events reported.

New Rule for Predicting Postoperative Atrial Fibrillation

MPO concentrations in selectively drained pericardial fluid were 25-fold higher than mixed drainage samples and 1,648-fold higher than serum levels (both p

New Blood Marker Predicts Future Asthma Attacks

Sphingolipid-to-steroid ratios in blood accurately predict asthma attacks years in advance, offering a new precision medicine tool for asthma care.

Shingles Vaccine May Slow Biological Ageing

New research suggests shingles vaccination may slow biological ageing and reduce inflammation, supporting healthier ageing beyond infection prevention.

ctDNA Levels Predict Treatment Response in Breast Cancer

Low baseline ctDNA and early clearance during treatment are strongly associated with improved response and survival in advanced breast cancer, highlighting ctDNA as a promising predictive and surrogate biomarker.